TIRZEPATIDE

Tirzepatide is a synthetic 39-amino acid peptide engineered as a dual agonist at the GLP-1 and GIP receptors. It is supplied as a lyophilized powder as a reference compound for laboratory research only.

Tirzepatide is a 39-residue peptide with the molecular formula C225H348N48O68, a molecular weight of approximately 4813.5 g/mol, and CAS number 2023788-19-2. It carries alpha-aminoisobutyric acid at positions 2 and 13 and a C20 fatty diacid conjugated to a lysine side chain.

A dual agonist activates two distinct receptors. Tirzepatide acts at both the GLP-1 and GIP receptors, where single-agonist peptides such as Semaglutide engage only GLP-1. The design question this raises, whether simultaneous activation produces additive or distinct downstream signaling, is what makes the compound a research subject.

Glucose-dependent insulinotropic polypeptide is a gut-derived incretin hormone that amplifies insulin release in response to nutrient intake and is studied in nutrient partitioning and fat storage pathways. It is the pathway that GLP-1-only agonists leave untouched.

Receptor coverage. Semaglutide is a single-receptor GLP-1 agonist; Tirzepatide adds GIP receptor activity. Comparing the two is the standard way to isolate what the GIP arm contributes, since they otherwise occupy the same incretin space.

Receptor count again. Tirzepatide is a dual GIP and GLP-1 agonist. Retatrutide adds glucagon receptor activity for a triple agonist. Together with Semaglutide the three form a single-, dual-, and triple-agonist series, which is why they are frequently studied as a set.

Alpha-aminoisobutyric acid is an unnatural amino acid placed at positions 2 and 13. The residue at position 2 blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native incretin peptides. Aib also constrains the peptide backbone in ways natural residues do not.

The C20 diacid promotes reversible albumin binding, which slows clearance and extends plasma residence. This is the same acylation strategy used in Semaglutide and Cagrilintide, and it is a standard approach to lengthening peptide duration in circulation.

No. Published characterization describes it as an imbalanced dual agonist, binding the GIP receptor with higher affinity than the GLP-1 receptor. That asymmetry is itself a research variable, since it means the two pathways are not engaged to equal degrees.

Common applications include receptor-binding affinity studies, downstream cAMP signaling response profiles, beta-cell activity models, incretin receptor pharmacology, and comparative single- versus dual-agonist mechanism research.

Because the comparison isolates the contribution of the second receptor. Running Tirzepatide alongside a GLP-1-only agonist under identical conditions is how researchers determine whether simultaneous incretin activation alters signaling kinetics rather than simply adding two effects together.

Tirzepatide is offered in 10 mg, 20 mg, 30 mg, 60 mg, and 100 mg vials. All are the same compound and purity; the difference is the quantity of lyophilized peptide in the vial.

Purity is 99% or greater as verified by HPLC. Each lot ships with third-party analytical documentation including HPLC and mass spectrometry data.

Store the lyophilized vial at -20 degrees Celsius, protected from light and moisture. Once reconstituted with bacteriostatic water, refrigerate the solution at 2-8 degrees Celsius and follow your laboratory's established protocols.

Our peptides require a doctor referral. If you do not have one, use the Get a Prescription button to start a telehealth consultation, and your approved products will unlock on your account.